Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

AAV production and purification v1

View through CrossRef
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available. In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart. The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression. The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience. We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims. The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing. *IMPORTANT* This protocol is based on Challis et al., Nat Protoc 14: 379, published in 2019. Since that publication, we have made a number of modifications to the protocol to increase throughput or yield. With these modifications, we routinely achieve yields of >5e12 vg per 150 cm dish, with a well packaging capsid (e.g. AAV9, AAV-PHP.eB, and AAV.CAP-B10). In Challis et al., Nat Protoc 14: 379, a Type 70 Ti rotor is used for ultracentrifugation of the AAV through a density gradient (steps 32-36). This rotor can hold 8 tubes, allowing for simultaneous purification of 8 separate AAV variants, at 1-10 plates (150 mm plates) per variant. To increase throughput, we also provide a smaller scale purification workflow with a Type 70.1 Ti rotor, which can allow for purification of 12 separate AAV variants, at 1-3 plates (150 mm plates) per variant. Significant modifications to the referenced protocol are indicated by *MODIFICATION*. Read and understand the original protocol, before following a modified protocol. Following the original protocol should also yield expected results.
Title: AAV production and purification v1
Description:
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems.
However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available.
In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart.
The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression.
The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience.
We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims.
The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing.
*IMPORTANT* This protocol is based on Challis et al.
, Nat Protoc 14: 379, published in 2019.
Since that publication, we have made a number of modifications to the protocol to increase throughput or yield.
With these modifications, we routinely achieve yields of >5e12 vg per 150 cm dish, with a well packaging capsid (e.
g.
AAV9, AAV-PHP.
eB, and AAV.
CAP-B10).
In Challis et al.
, Nat Protoc 14: 379, a Type 70 Ti rotor is used for ultracentrifugation of the AAV through a density gradient (steps 32-36).
This rotor can hold 8 tubes, allowing for simultaneous purification of 8 separate AAV variants, at 1-10 plates (150 mm plates) per variant.
To increase throughput, we also provide a smaller scale purification workflow with a Type 70.
1 Ti rotor, which can allow for purification of 12 separate AAV variants, at 1-3 plates (150 mm plates) per variant.
Significant modifications to the referenced protocol are indicated by *MODIFICATION*.
Read and understand the original protocol, before following a modified protocol.
Following the original protocol should also yield expected results.

Related Results

The Use of Adeno-associated virus (AAV) in Vaccine Development
The Use of Adeno-associated virus (AAV) in Vaccine Development
  Adeno-associated virus (AAV) is a very tiny (20-26 nm) icosahedral and non-enveloped virus, and it belongs to the Parvoviridae family. AAV vectors are the most widely used ...
AAV production and purification v1
AAV production and purification v1
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed ...
AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence
AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence
Abstract HIV-1 persists in latent reservoirs within CD4 cells, posing a major barrier to cure. Chimeric antigen receptor (CAR) T-cell therapy has shown promise against ...
Comprehensive Analysis of Sex Differences at Disease Manifestation in ANCA-Associated Glomerulonephritis
Comprehensive Analysis of Sex Differences at Disease Manifestation in ANCA-Associated Glomerulonephritis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small vessel vasculitis affecting multiple organ systems, including the kidney. Besides investigations ...
Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been traditionally treated using glucocorticoids and immunosuppressants. However, these treatment modes ...
Contrasting genetic association of IL2RAwith SLE and ANCA – associated vasculitis
Contrasting genetic association of IL2RAwith SLE and ANCA – associated vasculitis
AbstractBackgroundAutoimmune diseases are complex and have genetic and environmental susceptibility factors. The objective was to test the genetic association of systemic lupus ery...
Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Genetic Engineering of AAV Capsid Gene for Gene Therapy Application
Adeno-associated virus (AAV) is a promising vector for in vivo gene therapy because of its excellent safety profile and ability to mediate stable gene expression in human subjects....

Back to Top